PET-detected pneumonitis following curative-intent chemoradiation in non-small cell lung cancer (NSCLC): recognizing patterns and assessing the impact on the predictive ability of FDG-PET/CT response assessment

Amir Iravani; Guy-Anne Turgeon; Tim Akhurst; Jason W Callahan; Mathias Bressel; Sarah J Everitt; Shankar Siva; Michael S Hofman; Rodney J Hicks; David L Ball; Michael P Mac Manus

Journal article

PET-detected pneumonitis following curative-intent chemoradiation in non-small cell lung cancer (NSCLC): recognizing patterns and assessing the impact on the predictive ability of FDG-PET/CT response assessment

Amir Iravani, Guy-Anne Turgeon, Tim Akhurst, Jason W Callahan, Mathias Bressel, Sarah J Everitt, Shankar Siva, Michael S Hofman, Rodney J Hicks, David L Ball, Michael P Mac Manus

EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING | SPRINGER | Published : 2019

DOI: 10.1007/s00259-019-04388-3

Abstract

PURPOSE: Inflammatory FDG uptake in the lung (PET-pneumonitis) following curative-intent radiotherapy (RT)/chemo-RT (CRT) in non-small cell lung cancer (NSCLC) can pose a challenge in FDG-PET/CT response assessment. The aim of this study is to describe different patterns of PET-pneumonitis to guide the interpretation of FDG-PET/CT and investigate its association with tumor response and overall survival (OS). METHODS: Retrospective analysis was performed on 87 NSCLC patients in three prospective trials who were treated with radical RT (n = 7) or CRT (n = 80), with baseline and post-treatment FDG-PET/CT. Visual criteria were performed for post-treatment FDG-PET/CT response assessment. The grad..

View full abstract

University of Melbourne Researchers

Michael Hofman Author The Sir Peter Maccallum Department of Oncology

Tim Akhurst Author Medicine - St Vincent's Hospital

David Ball Author The Sir Peter Maccallum Department of Oncology

Sarah Everitt Author The Sir Peter Maccallum Department of Oncology

Michael MacManus Author The Sir Peter Maccallum Department of Oncology

Related Projects (3)

Biologically individualised treatment for lung cancer

Positron Emission Tomography (PET)/Computed Tomography (CT) scanners pinpoint the location of cancer cells in people prior to and after trea..

MOLECULAR IMAGING AS A CRITICAL TOOL IN DISCOVERY OF THE BASIS OF TUMOUR HETEROGENEITY AND DEVELOPING NOVEL THERAPIES TO OVERCOME THERAPEUTIC RESISTANCE

Determining treatment options for cancer currently relies on the size and extent of tumour deposits on imaging, combined with a biopsy. Howe..

USING NEW LUNG IMAGING AND BIOLOGIC MARKERS TO IMPROVE RADIOTHERAPY FOR LUNG CANCER

Grants

Awarded by National Health and Medical Research Council (NHMRC)

Awarded by NHMRC

Awarded by Cancer Australia Priority-driven Collaborative Cancer Research Scheme

Awarded by NHMRC Practitioner Fellowship

Funding Acknowledgements

No funding was received for this study. However, the <SUP>18</SUP>F-FLT/18F-FDG study (Australian Clinical Trials Registry: ACTRN12611001283965) work was supported by the National Health and Medical Research Council (NHMRC) (grant number APP1003895) and the Victorian Cancer Agency. The <SUP>68</SUP>Ga-Ventilation/perfusion PET (Universal Trial Number: U1111-1138-4421) study was supported by funding from the NHMRC (grant number APP1038399) and from the Cancer Australia Priority-driven Collaborative Cancer Research Scheme (Project No. 1060919). Professor Hicks is supported by an NHMRC Practitioner Fellowship (APP1108050).